RxDoctor Payments DataLook up a doctor →

Raj Parikh

Pulmonary Disease · Hartford, CTNPI 1790122794

Payments from drug & device makers

$419,062in general payments, 2019–2025

Across 618 payments — averaging $678.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$173K
  • Actelion Pharmaceuticals US, Inc.$172K
  • Merck$68K
  • Chiesi USA, Inc.$4K
  • GSK$946
  • Boston Scientific$174
  • plus $595 from 14 others

What the payments were for

  • Consulting fees$30,4388%
  • Speaking & faculty fees$306,24279%
  • Travel & lodging$39,56910%
  • Food & beverage$9,8213%
  • Education$3150%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$419,062 in reported general payments places this provider in the 95th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$178,056
Medicare patients
349
Services billed
1,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil132$3,263,634
AdempasRiociguat129$1,793,361
UptraviSelexipag44$1,121,746
OpsumitMacitentan78$994,588
WinrevairSotatercept-Csrk35$550,176
Orenitram ErTreprostinil Diolamine36$371,113
OpsynviMacitentan/Tadalafil21$269,991
Tadalafil297$268,579
Ambrisentan114$214,017
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$46,243
EliquisApixaban49$37,766
Sildenafil Citrate34$24,574
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$23,742
Breo ElliptaFluticasone/Vilanterol17$13,228
Spiriva HandihalerTiotropium Bromide17$7,581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Opsynvi$172,411$2,386,326143 claims
BayerAdempas$40$1,793,361129 claims
MerckWinrevair$67,755$550,17635 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$946$83,21295 claims
AstraZenecaBreztri Aerosphere$80$6,75011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →